RxDoctor Payments DataLook up a doctor →

Adriana Ros, DO

Dermatology · Clifton, NJNPI 1942468392

Payments from drug & device makers

$132,773in general payments, 2019–2025

Across 849 payments — averaging $156.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arcutis Biotherapeutics, Inc.$59K
  • AbbVie$41K
  • Kowa Pharmaceuticals America, Inc.$13K
  • Pfizer$6K
  • Journey Medical Corporation$3K
  • EPI Health, LLC$2K
  • plus $11K from 42 others

What the payments were for

  • Consulting fees$41,68631%
  • Speaking & faculty fees$62,70447%
  • Travel & lodging$12,84410%
  • Food & beverage$14,97911%
  • Education$5600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$132,773 in reported general payments places this provider in the 95th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$239,667
Medicare patients
570
Services billed
2,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$296,579
Cosentyx Sensoready (2 Pens)Secukinumab29$243,535
Humira(Cf) PenAdalimumab21$139,921
Taltz AutoinjectorIxekizumab17$113,799
OtezlaApremilast15$86,772
Dupixent PenDupilumab18$69,028
OpzeluraRuxolitinib Phosphate11$22,208
Clobetasol Propionate124$7,838
Calcipotriene35$6,612
Tacrolimus63$6,097
Ketoconazole261$4,363
Betamethasone Dipropionate23$2,762
Fluorouracil32$2,251
Ammonium Lactate66$1,832
Azelaic Acid19$1,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$193$86,77215 claims
Incyte CorporationOpzelura$568$22,20811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 394 dermatology providers in New Jersey.

Other dermatology in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →